The Covid-19 vaccine from Astrazeneca has taken some hits since last week, when the European Medicines Agency (EMA) confirmed that the EMA's safety experts sees a possible connection between this vaccine and a series of rare but highly serious, and sometimes fatal, side effects.
Even though many countries have limited their use of the vaccine, and some – like Denmark – have opted to suspend it immediately, it does not seem like this will have any financial consequences for Astrazeneca. This firm runs all of its global vaccine sales as a non-profit project, and the company is regretful about the fact that people seem to forget this, as criticism is raining down on Astrazeneca in relation to the possible side effects of the vaccine on the one hand, and overdue deliveries on the other.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"
Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Coloplast upgrades growth expectations following acquisition
Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.
Demant's surgical division loses president of 13 years
Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.
Hearing aid market in US grew by 37 percent in 2021
Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.
Lundbeck's migraine drug approved in EU
Vyepti has become the first approved intravenous preventative migraine treatment in the region.
Design Control Specialist / System Engineer 
Lead Scientist, Global STA, Royal DSM/Glycom 
Senior Scientist 
Health Economist 
Commercial Excellence Lead 
Senior Manager/Associate Director Regulatory Affairs 
Senior Associate, CMC Pharmaceutical Development 
Associate Director, GMP QA, Biologics/Radiopharmaceuticals 
QA Manager GMP/GDP Compliance & Audits 
Chemists are wanted for ALK's internal Aircraft Corps 
QA Specialist